



Company Announcement

Nykode Therapeutics to Present a Poster on Interim Results from the Pre-planned Interim Analysis from the C-02 trial with VB10.16 in advanced cervical patients at the European Society of Gynaecological Oncology's 23rd Annual Meeting (ESGO 2022)

Oslo, Norway, October 28, 2022 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the presentation of a poster at the European Society of Gynaecological Oncology's 23rd Annual Meeting, being held in Berlin, October 27-30. The presentations will include results from a pre-planned interim analysis of the VB C-02 trial with VB10.16, Nykode's wholly owned therapeutic DNA vaccine specifically targeting antigen presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer.

The new data further supports the use of specific blood based biomarkers as prognostic and predictive factors of treatment outcome.

Michael Engsig, Nykode's Chief Executive Officer, stated: "It is a great opportunity to present the VB C-02 interim data, including data that have not been released before, to the scientific community at ESGO. We look forward to continue updating the scientific community as we dive deeper into the interim data of VB C-02 to further our understanding of how VB10.16 works to the benefit of patients and how biomarkers can be used to predict clinical outcome."

Poster accepted for presentation at ESGO 2022

Abstract ID 447; PA-004:

- Efficacy and safety of VB10.16, therapeutic DNA vaccine specifically targeting antigen presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis

The poster will be made available in the Scientific Papers and Presentations section of the Company's website at <https://nykode.com/innovation-and-research/scientific-papers-and-presentations/>



About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group. Additionally, Nykode is conducting a Phase 1/2 trial with next-generation COVID-19 vaccine candidates.

The Company's partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

Chief Business Officer, Agnete Fredriksen
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway